Tag results:
T-cell lymphoma
Umbilical & Placental Cell News
Allogeneic Hematopoietic Stem Cell Transplantation from Unmanipulated Haploidentical Donor and Unrelated Cord Blood for T-cell Lymphoma: A Retrospective Study from the Société Francophone De...
[Bone Marrow Transplantation] The authors evaluated the outcome of recipients of alternative donor allogeneic stem cell transplantation for T-cell lymphoma.
Human Immunology News
Multimodal Single-Cell Analysis of Cutaneous T Cell Lymphoma Reveals Distinct Sub-Clonal Tissue-Dependent Signatures
[Blood] To identify and interrogate malignant clones in matched skin and blood from leukemic MF and SS patients, we combine T cell receptor clonotyping, with quantification of gene expression and cell surface markers at the single cell level.
Extracellular Matrix News
High-Dimensional and Single-Cell Transcriptome Analysis of the Tumor Microenvironment in Angioimmunoblastic T Cell Lymphoma (AITL)
[Leukemia] Scientists utilized mass cytometry and single-cell transcriptome analysis to identify several expanded populations within the angioimmunoblastic T-cell lymphoma tumor microenvironment.
Human Immunology News
A Novel lncRNA TCLlnc1 Promotes Peripheral T Cell Lymphoma Progression through Acting as a Modular Scaffold of HNRNPD and YBX1 Complexes
[Cell Death & Disease] In this research, a novel lncRNA was identified overexpressed in the main subtypes of peripheral T cell lymphoma, and designated as T cell lymphoma-associated lncRNA1.
Immune Regulation News
FYN–TRAF3IP2 Induces NF-κB Signaling-Driven Peripheral T-Cell Lymphoma
[Nature Cancer] Consistent with a driver oncogenic role, FYN–TRAF3IP2 expression in hematopoietic progenitors induced NF-κB-driven T-cell transformation in mice and cooperated with loss of the Tet2 tumor suppressor in peripheral T-cell lymphoma development.
Human Immunology News
Combination of Anti-PD-1 Antibody with P-GEMOX as a Potentially Effective Immunochemotherapy for Advanced Natural Killer/T Cell Lymphoma
[Signal Transduction and Targeted Therapy] Scientists report the efficacy of anti-programmed death 1 antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced natural killer/T cell lymphoma.